# Executive Summary
# An Evaluation of Prescription Drug Monitoring Programs

**By Ronald Simeone and Lynn Holland**
**Simeone Associates, Inc.**

Overview

- At the time of the study, 20 states had implemented systems to monitor the prescription and sale of drugs identified as controlled substances by the U.S. Drug Enforcement Administration.

- Another 23 states were in the process of designing or planning to design such systems.

- This growth had been fueled in part by the U.S. Department of Justice's Harold Rogers Prescription Drug Monitoring Program (PDMP). States are eligible to receive funding if they have in place, or have pending, an enabling statute or regulation requiring the submission of controlled substance prescription data to a central database.

- As implemented at the state level, PDMP's purpose is to reduce the abuse of controlled pharmaceutical substances.

- This study examines two routes by which PDMPs might affect the probability of prescription drug abuse:
  - Indirectly—operating through the supply of controlled substances. If a PDMP reduces the supply of prescription drugs (perhaps by regulating prescribing behavior), then this in turn may affect the probability of abuse.
  - Directly—when supply is held constant, a PDMP may itself reduce the probability of abuse (perhaps by regulating dispensing behavior).

Types of PDMPs

- States with PDMPs differ in how they identify and investigate cases:
  - States with reactive PDMPs—generate solicited reports only in response to a specific inquiry made by a prescriber, dispenser, or other party with appropriate authority.
  - States with proactive PDMPs—identify and investigate cases, generating unsolicited reports whenever suspicious behavior is detected, and tend to be law enforcement-oriented in their approach.

- States with PDMPs also differ in their scope of coverage:
  - At one extreme, including only Schedule II drugs.
  - At the other extreme, including Schedule II-V drugs.
  - Schedule II drugs generally include pain relievers that can have addictive qualities.

Supply Data

- This study limited its scope to include Schedule II pain relievers and stimulants only—as these drugs have the greatest potential for abuse. Defining the problem in this way also mitigated the role of Internet drug sales. The Automation of Reports and Consolidated Orders

System was used to provide information on each state's supply over a specific period (1997-2003).

- To allow comparisons among states to be made, potency-adjusted measures were developed for each drug and expressed as grams per capita.

Abuse Data
- The Treatment Episode Data Set, maintained by the U.S. Department of Health and Human Services' Substance Abuse and Mental Health Services Administration, includes all individuals admitted to state-licensed drug treatment programs in the United States.

- For the purposes of this study, abuse is measured as admission to treatment where the primary, secondary, or tertiary substance of abuse is a prescription pain reliever or a prescription stimulant.

Principal Findings
- The presence of a PDMP reduces the per capita supply of prescription pain relievers and stimulants, reducing the probability of abuse for these drugs.

- States that are proactive in their approach to regulation may be more effective in reducing the per capita supply of prescription pain relievers and stimulants than states that are reactive in their approach to regulation. States that are law enforcement-oriented thus may be more effective in curbing abuse.

- A statistical simulation showed that by 2003, the rate of pain reliever abuse would have been 10.1 percent higher and the rate of stimulant abuse would have been 4.1 percent higher in the absence of proactive regulatory control. (Figures 27 and 28 below are from the full report, where "XPDMP" is used to denote proactive PDMP status. The results are expressed as admissions per 100,000).

Figure 27: Pain Reliever Admissions in XPDMP States

Figure 28: Stimulant Admissions in XPDMP States